Semi-Annual Report — FY2026 H1
What Noile-Immune Biotech Inc. reported for the period from 2026-01-01 to 2026-12-31. Filed by ノイルイミューン・バイオテック株式会社
Filed 2026-08-13View the original on EDINET
How much it says
48Typical
What moved here
23named for the first time
Its own wording
26terms
Which filing this is
9/ 9newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the current interim accounting period, the company continued R&D in drug discovery for cancer immunotherapy and disclosed, among other matters, that dosing was administered in the Phase I clinical trial for its proprietary pipeline program NIB103. It also stated that NIB104 was selected for AMED's FY2026 Translational Research Program and that the company is participating as a partner company.
Komori's summary of this document, not the document's own words.48Typical
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 35 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
37
Thin
60
Detailed
50
Typical
0
Almost nothing
53
Typical
71
Detailed
62
Detailed
53
Typical
55
Typical
10
Almost nothing
R&D spend2億円Money spent making new things.
Cash left over-4億円Cash from the business, less what went into equipment.
Spent on equipmentNot disclosedThis document does not carry the figure.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.